Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
- Resource Type
- Source
- The Lancet. Respiratory medicine, 8 (5
- Subject
Diarrhea Male Pulmonary and Respiratory Medicine medicine.medical_specialty Indoles Vital Capacity Population nintedanib, idiopathic pulmonary fibrosis Settore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIO behavioral disciplines and activities law.invention 03 medical and health sciences chemistry.chemical_compound Idiopathic pulmonary fibrosis FEV1/FVC ratio 0302 clinical medicine Double-Blind Method Randomized controlled trial law Internal medicine nintedanib medicine Humans 030212 general & internal medicine education Protein Kinase Inhibitors Idiopathic interstitial pneumonia Aged education.field_of_study business.industry Interstitial lung disease Nausea Middle Aged respiratory system Sciences bio-médicales et agricoles medicine.disease Idiopathic Pulmonary Fibrosis respiratory tract diseases body regions 030228 respiratory system chemistry Disease Progression Female Nintedanib business Hypersensitivity pneumonitis - Language
- English